Hypothermia Versus Normothermia After Extracorporeal Cardiopulmonary Resuscitation for Out-of-hospital Cardiac Arrest
Launched by KAGAWA UNIVERSITY · Jan 14, 2025
Trial Information
Current as of November 13, 2025
Recruiting
Keywords
ClinConnect Summary
The SAVE-J NEUROTHERM trial is studying how different temperature treatments—hypothermia (cooling the body) versus normothermia (keeping the body at normal temperature)—affect patients who have experienced a sudden cardiac arrest outside of the hospital and received a life-saving procedure called extracorporeal cardiopulmonary resuscitation (ECPR). Researchers want to find out which approach can help reduce the risk of death and improve brain function after such an event.
To participate in this trial, potential volunteers should be between 18 and 75 years old and have had an out-of-hospital cardiac arrest, specifically with certain heart rhythms that make the situation critical. However, there are some conditions that would exclude someone from joining, such as if their heart started beating again before receiving ECPR or if they have certain other health issues. Participants in the trial will be monitored closely to see how well they respond to the different temperature treatments, and their outcomes will help guide future care for patients in similar situations.
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • OHCA
- • Age of 18-75 years, known or estimated
- • An initial cardiac arrest rhythm of ventricular fibrillation/pulseless ventricular tachycardia or pulseless electrical activity
- Exclusion Criteria:
- • ECMO initiated after sustained return of spontaneous circulation (ROSC) and patients with sustained ROSC before ECMO initiation
- • OHCA of presumed non-cardiac etiology
- • Time from emergency call or witnessed arrest to hospital arrival of \>60 min
- • Time from hospital arrival to ECMO initiation of \>60 min
- • Pre-hospital ECPR
- • Unavailability of the ECMO heat exchanger for temperature control
- • Glasgow Coma Scale score before temperature control of \>8
- • Core body temperature upon hospital arrival of ≤32ºC
- • Surgical intervention before temperature control (e.g., surgical intervention for the primary disease or complications related to resuscitation/ECMO procedures)
- • Do Not Attempt Resuscitation) order confirmed prior to temperature control
- • Limitations in intensive care before temperature control
- • Known cerebral performance category (CPC) of 3-4 before cardiac arrest
- • Known chronic obstructive pulmonary disease with home oxygen therapy
- • Known or suspected pregnancy
- • Concomitant illness, such as malignancy, shortens life expectancy (180-day survival unlikely)
- • Consent not obtained or withdrawn by the participant or surrogate
- • Other reasons, physician's decision not to enroll the patient
About Kagawa University
Kagawa University is a prestigious academic institution located in Japan, known for its commitment to advancing medical research and education. As a clinical trial sponsor, Kagawa University leverages its extensive expertise in health sciences to conduct innovative research aimed at improving patient outcomes. The university fosters collaboration among multidisciplinary teams, integrating cutting-edge technology and methodologies to address critical healthcare challenges. With a focus on ethical standards and regulatory compliance, Kagawa University is dedicated to contributing valuable insights to the scientific community and enhancing evidence-based medical practices through its clinical trials.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Kyoto, Japan
Tokyo, Japan
Tokyo, Japan
Sendai, Miyagi, Japan
Tokyo, Japan
Tokyo, Japan
Okayama, Japan
Tokyo, Japan
Sapporo, Hokkaido, Japan
Suita, Osaka, Japan
Kagawa, Japan
Sapporo, Hokkaido, Japan
Sendai, Miyagi, Japan
Asahikawa, Hokkaido, Japan
Sapporo, Hokkaido, Japan
Tachikawa, Tokyo, Japan
Yokohama, Kanagawa, Japan
Okayama, Japan
Sendai, Miyagi, Japan
Kurume, Fukuoka, Japan
Tokyo, Japan
Tokyo, Japan
Kurume, Fukuoka, Japan
Ebina, Kanagawa, Japan
Musashino, Tokyo, Japan
Saitama, Japan
Yokohama, Kanagawa, Japan
Tokyo, Japan
Tsuyama, Okayama, Japan
Asahikawa, Hokkaido, Japan
Kobe, Japan
Kakogawa, Hyogo, Japan
Toyooka, Hyogo, Japan
Oshima, Kagoshima, Japan
Kyoto, Japan
Okinawa, Japan
Tokyo, Japan
Tottori, Japan
Sapporo, Hokkaido, Japan
Kakogawa, Hyogo, Japan
Kobe, Hyogo, Japan
Toyooka, Hyogo, Japan
Kita Gun, Kagawa, Japan
Amami, Kagoshima, Japan
Ebina, Kanagawa, Japan
Sendai, Miyagi, Japan
Tsuyama, Okayama, Japan
Shimajiri Gun, Okinawa, Japan
Suita, Osaka, Japan
Saitama, Japan
Tokyo, Japan
Tokyo, Japan
Tokyo, Japan
Tokyo, Japan
Tokyo, Japan
Tottori, Japan
Patients applied
Trial Officials
Akihiko Inoue
Principal Investigator
Hyogo Emergency Medical Center
Yasuhiro Kuroda
Study Chair
Kagawa University
Toru Hifumi
Study Chair
Kyorin University School of Medicine
Tetsuya Sakamoto
Study Director
Teikyo University
Naoaki Ichihara
Study Director
Osaka University
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported